These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 27686810)
21. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs). Lu Y; Mao F; Li X; Zheng X; Wang M; Xu Q; Zhu J; Li J J Med Chem; 2017 Jun; 60(12):5099-5119. PubMed ID: 28541695 [TBL] [Abstract][Full Text] [Related]
22. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. Blay JY; Casali PG; Dei Tos AP; Le Cesne A; Reichardt P Oncology; 2015; 89(1):1-13. PubMed ID: 25720422 [TBL] [Abstract][Full Text] [Related]
25. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors. Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309 [TBL] [Abstract][Full Text] [Related]
26. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971 [TBL] [Abstract][Full Text] [Related]
27. New therapeutic agents in gastrointestinal stromal tumours. Falkenhorst J; Hamacher R; Bauer S Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566 [TBL] [Abstract][Full Text] [Related]
29. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875 [TBL] [Abstract][Full Text] [Related]
31. Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies. Hedenström P; Nilsson B; Demir A; Andersson C; Enlund F; Nilsson O; Sadik R World J Gastroenterol; 2017 Aug; 23(32):5925-5935. PubMed ID: 28932084 [TBL] [Abstract][Full Text] [Related]
32. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624 [TBL] [Abstract][Full Text] [Related]
33. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor. Kou Y; Yang R; Wang Q J Biosci; 2018 Dec; 43(5):1015-1023. PubMed ID: 30541960 [TBL] [Abstract][Full Text] [Related]
34. [Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs]. Kalfusová A; Kodet R Cesk Patol; 2017; 53(4):167-173. PubMed ID: 29227120 [TBL] [Abstract][Full Text] [Related]
35. Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit. Pelczar P; Zibat A; van Dop WA; Heijmans J; Bleckmann A; Gruber W; Nitzki F; Uhmann A; Guijarro MV; Hernando E; Dittmann K; Wienands J; Dressel R; Wojnowski L; Binder C; Taguchi T; Beissbarth T; Hogendoorn PC; Antonescu CR; Rubin BP; Schulz-Schaeffer W; Aberger F; van den Brink GR; Hahn H Gastroenterology; 2013 Jan; 144(1):134-144.e6. PubMed ID: 23041331 [TBL] [Abstract][Full Text] [Related]
36. An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor. Gheysen M; Vander Borght S; Lehnert S; Vanslembrouck R; Vanden Bempt I; Schöffski P Oncol Res Treat; 2020; 43(9):470-473. PubMed ID: 32640452 [TBL] [Abstract][Full Text] [Related]
37. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges. Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553 [TBL] [Abstract][Full Text] [Related]
38. Current research and treatment for gastrointestinal stromal tumors. Lim KT; Tan KY World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140 [TBL] [Abstract][Full Text] [Related]
39. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [TBL] [Abstract][Full Text] [Related]
40. Molecular pathobiology of gastrointestinal stromal sarcomas. Corless CL; Heinrich MC Annu Rev Pathol; 2008; 3():557-86. PubMed ID: 18039140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]